April 21: INSULIN Act introduced.

The American Diabetes Association (ADA) applauds the introduction of the bipartisan Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act by Sens. Jeanne Shaheen (D-NH) and Susan Collins (R-ME) today. The ADA has been the leading advocate for limiting cost-sharing for insulin at both the state and federal levels and increasing access to affordable insulin for both insured and uninsured people with diabetes. One in four people who use insulin report rationing this lifesaving drug, and our first priority is reducing costs for patients. In addition to limiting cost-sharing for insulin to $35 per month for individuals with commercial insurance plans, the INSULIN Act makes sure rebates stop inflating the price of insulin, biosimilar insulins can come to market more quickly, and insurers make these more affordable options available to patients. The ADA strongly urges Congress to pass the bipartisan INSULIN Act as soon as possible, for the nearly eight million Americans who rely on insulin to survive.
 
Click here for more information about the INSULIN Act.

March 16, 2023: Sanofi announces insulin price cuts.

“The American Diabetes Association (ADA) is the leading voice advocating for insulin affordability and is working to ensure that all people with diabetes have access to the care they need. The ADA has led the charge to enact cost-sharing limits on insulin in 22 states and D.C., and the first-ever federal copay cap in Medicare. We are encouraged that all of the major manufacturers have taken steps to make insulin more affordable, but the fight is not over. We will continue advocating for efforts in Congress and states across the country to ensure insulin is affordable to everyone with diabetes who relies on it to survive.”- Lisa Murdock, ADA Chief Advocacy Officer

March 14, 2023: Novo Nordisk announces insulin price reduction.

“The American Diabetes Association® (ADA) is the leading voice advocating for insulin affordability and is working to ensure that all people with diabetes have access to the care they need. The ADA has led the charge to enact cost-sharing limits on insulin in 22 states and D.C., and now the first-ever federal copay cap in Medicare. We are pleased that more manufacturers are continuing to take steps to make insulin more affordable, and we hope others follow suit. ADA will keep working to make sure drug rebates are not inflating costs for patients at the pharmacy counter, and we will continue to support efforts to provide affordable insulin to everyone with diabetes who relies on it to survive.” - Lisa Murdock, ADA Chief Advocacy Officer

To learn more about insulin cost and affordability and to join ADA in the fight for affordable insulin, visit diabetes.org/insulincost.

March 1, 2023: Lilly announces cost-sharing limits on insulin. ADA resource available for more information.

“The American Diabetes Association (ADA) is the leading voice advocating for insulin affordability and is working to ensure that all people with diabetes have access to the care they need. We applaud Eli Lilly for taking the important step to limit cost-sharing for its insulin, and we encourage other insulin manufacturers to do the same. While we have been able to help achieve significant progress on the issue of insulin affordability, including Medicare’s new out-of-pocket cost cap on insulin, state copay caps, and patient assistance developments from insulin manufacturers, we know that our work is not done. We will work to ensure that Eli Lilly’s patient assistance program is benefiting patients as intended and continue the fight so that everyone who needs insulin has access.”  — Charles “Chuck” Henderson, CEO of the American Diabetes Association

To learn more about insulin cost and affordability and to join ADA in the fight for affordable insulin, visit diabetes.org/insulincost. To lead more about manufacturer patient programs, visit insulinhelp.org.

Feb. 23, 2023: Ozempic shortage continues. What you need to know.

Semaglutides, such as Ozempic and and other medications to treat type 2 diabetes continue to be in short supply in many areas of the country. These medications are an important tool for people with type 2 diabetes, but they are also prescribed for weight loss. Not only do they lower blood glucose and weight, but they have been shown to decrease cardiovascular events for those living with diabetes.

The manufacturers of these medications are working to address the shortage, and the ADA continues to monitor the situation. In the meantime, if you are not able to get the medication you use from your pharmacy, contact a member of your medical care team to determine what other options are right for you.

Jan. 1, 2023: Medicare insulin price cap goes into effect.

After tremendous advocacy from the ADA, the $35 price cap on insulin for people on Medicare Part D goes into effect today. Similar caps will go into effect on July 1, 2023, for people on Medicare Part B. Visit Medicare.gov for more information.